Patents Assigned to Bridge Pharma, Inc.
-
Patent number: 11197851Abstract: Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.Type: GrantFiled: February 17, 2021Date of Patent: December 14, 2021Assignee: BRIDGE PHARMA INC.Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo, Kresimir Pucaj
-
Patent number: 10959992Abstract: Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.Type: GrantFiled: July 30, 2020Date of Patent: March 30, 2021Assignee: BRIDGE PHARMA INC.Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo, Kresimir Pucaj
-
Patent number: 9808419Abstract: The methods disclosed herein relate to the treatment of dermal infectious disorders, in human patients, by administering a therapeutically effective amount of RS-norketotifen.Type: GrantFiled: March 16, 2016Date of Patent: November 7, 2017Assignee: BRIDGE PHARMA, INCInventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
-
Patent number: 9694003Abstract: Disclosed herein are methods of treating a mammal in need of a reduction in intraocular pressure by administering an intraocular formulation including a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the mammal in need thereof, wherein the intraocular formulation includes about 0.02 wt % to about 1.0 wt % norketotifen or a salt or an isomer thereof, calculated as the norketotifen free base. In certain aspects, the intraocular formulation is free from any added preservative and the intraocular formulation is self-preserving. Also included herein is a method of treating a human in need of a reduction in intraocular pressure by administering an intranasal formulation that includes a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the human in need thereof. Also, the beneficial effects of known drugs for high IOP are improved by co-administration with norketotifen.Type: GrantFiled: March 16, 2016Date of Patent: July 4, 2017Assignee: BRIDGE PHARMA, INC.Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo, Keith Johnson
-
Patent number: 9439895Abstract: Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of RS-norketotifen or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine H-1-, H-2- and H-4-receptor inhibitors. In certain aspects, the non-histaminergic pruritus is associated with diabetes.Type: GrantFiled: April 21, 2016Date of Patent: September 13, 2016Assignee: BRIDGE PHARMA, INC.Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
-
Patent number: 9345697Abstract: Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of RS-norketotifen or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine H-1-, H-2- and H-4-receptor inhibitors. In certain aspects, the non-histaminergic pruritus is associated with a dermal disorder, a psychological disorder, a mental disorder, a nerve disorder, or a systemic disorder.Type: GrantFiled: June 11, 2015Date of Patent: May 24, 2016Assignee: BRIDGE PHARMA, INC.Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
-
Patent number: 9333199Abstract: The methods disclosed herein relate to the treatment of histamine H-4-related pruritus associated with nerve disorders, by administering a combined histamine H-1 and H-4 receptor inhibitor, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described.Type: GrantFiled: August 7, 2015Date of Patent: May 10, 2016Assignee: BRIDGE PHARMA, INC.Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
-
Publication number: 20150272941Abstract: The methods disclosed herein relate to the treatment of chronic pulmonary disorders, such as for example asthma, COPD, cough, bronchial hyperactivity and bronchitis, in human patients, by administering a therapeutically effective amount of RS-norketotifen.Type: ApplicationFiled: October 29, 2013Publication date: October 1, 2015Applicant: BRIDGE PHARMA, INC.Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
-
Patent number: 9138431Abstract: The methods disclosed herein relate to the treatment of histamine H-4—related pruritus, by administering a histamine H-4 receptor inverse agonist that selectively accumulates at the biophases of the disorders, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described.Type: GrantFiled: August 6, 2013Date of Patent: September 22, 2015Assignee: BRIDGE PHARMA, INC.Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
-
Patent number: 8969385Abstract: Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.Type: GrantFiled: April 15, 2014Date of Patent: March 3, 2015Assignee: Bridge Pharma, Inc.Inventors: A. K. Gunnar Aberg, Keith Johnson
-
Patent number: 8778971Abstract: The methods disclosed herein relate to the treatment of skin infections in dogs, by administering a therapeutically effective amount of norketotifen. Therapeutic antimicrobial activity of norketotifen against Malassezia sp. is described.Type: GrantFiled: September 12, 2013Date of Patent: July 15, 2014Assignee: Bridge Pharma, Inc.Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
-
Patent number: 8765787Abstract: Self-preserving ophthalmic formulations containing norketotifen and methods of making the same and the use thereof in patients suffering from xerophthalmia are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof, self-preserving topical ophthalmic formulations containing norketotifen, free from any added preservative.Type: GrantFiled: November 20, 2009Date of Patent: July 1, 2014Assignee: Bridge Pharma, Inc.Inventors: A.K. Gunnar Aberg, Keith Johnson
-
Patent number: 8741930Abstract: Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment.Type: GrantFiled: December 24, 2008Date of Patent: June 3, 2014Assignee: Bridge Pharma, Inc.Inventors: A. K. Gunnar Aberg, Keith Johnson
-
Publication number: 20140120121Abstract: The methods disclosed herein relate to the treatment of atopic inflammatory disorders, such as dermal or pulmonary atopic inflammatory disorders, in humans, by administering a therapeutically effective amount of ractopamine.Type: ApplicationFiled: January 18, 2013Publication date: May 1, 2014Applicant: BRIDGE PHARMA, INC.Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
-
Publication number: 20140113936Abstract: The methods disclosed herein relate to the treatment of skin infections in dogs, by-administering a therapeutically effective amount of norketotifen. Therapeutic antimicrobial activity of norketotifen against Malassezia sp. is described.Type: ApplicationFiled: September 12, 2013Publication date: April 24, 2014Applicant: BRIDGE PHARMA, INC.Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
-
Patent number: 8557846Abstract: The methods disclosed herein relate to the treatment of dermal disorders, such as for example atopic dermatitis, in dogs, by administering a therapeutically effective amount of racemic norketotifen. Co-administrations with steroids or immunosuppressant drugs are described.Type: GrantFiled: January 11, 2013Date of Patent: October 15, 2013Assignee: Bridge Pharma, Inc.Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
-
Patent number: 8445542Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed.Type: GrantFiled: November 29, 2012Date of Patent: May 21, 2013Assignee: Bridge Pharma, Inc.Inventor: A. K. Gunnar Aberg
-
Publication number: 20130090295Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed.Type: ApplicationFiled: November 29, 2012Publication date: April 11, 2013Applicant: BRIDGE PHARMA, INC.Inventor: BRIDGE PHARMA, INC.
-
Patent number: 8383685Abstract: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.Type: GrantFiled: September 8, 2011Date of Patent: February 26, 2013Assignee: Bridge Pharma, Inc.Inventor: A. K. Gunnar Aberg
-
Publication number: 20120015895Abstract: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.Type: ApplicationFiled: September 8, 2011Publication date: January 19, 2012Applicant: BRIDGE PHARMA, INC.Inventor: A.K.Gunnar Aberg